{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=5-Flourouracil",
    "query": {
      "intervention": "5-Flourouracil"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-09T23:11:35.311Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04747470",
      "title": "Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "GS-3583",
          "type": "DRUG"
        },
        {
          "name": "Zimberelimab",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "5-Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2021-03-25",
      "completion_date": "2022-11-07",
      "has_results": true,
      "last_update_posted_date": "2024-09-03",
      "last_synced_at": "2026-09-09T23:11:35.311Z",
      "location_count": 4,
      "location_summary": "Grand Rapids, Michigan • New York, New York • Portland, Oregon + 1 more",
      "locations": [
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04747470"
    },
    {
      "nct_id": "NCT02358863",
      "title": "Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Esophageal Cancer",
        "Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "Modified FOLFOX6",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel/Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin/Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin/Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "IRI/EPI",
          "type": "DRUG"
        },
        {
          "name": "EPI/Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan/Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Georgetown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2015-02",
      "completion_date": "2016-11",
      "has_results": true,
      "last_update_posted_date": "2018-09-06",
      "last_synced_at": "2026-09-09T23:11:35.311Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02358863"
    },
    {
      "nct_id": "NCT04329221",
      "title": "Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cutaneous Squamous Cell Carcinoma",
        "Actinic Keratoses",
        "Skin Cancer",
        "Organ Transplant Recipients",
        "Immunotherapy"
      ],
      "interventions": [
        {
          "name": "Calcipotriol Only Product in Cutaneous Dose Form",
          "type": "DRUG"
        },
        {
          "name": "Vaseline",
          "type": "DRUG"
        },
        {
          "name": "Topical 5FU",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2026-01-01",
      "completion_date": "2030-01",
      "has_results": false,
      "last_update_posted_date": "2025-05-07",
      "last_synced_at": "2026-09-09T23:11:35.311Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • St Louis, Missouri",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04329221"
    },
    {
      "nct_id": "NCT01407107",
      "title": "Dose Escalation Trial of Nitroglycerin, 5-flourouracil and Rad Therapy for Rectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "Nitroglycerin 0.2 MG/HR",
          "type": "DRUG"
        },
        {
          "name": "Nitroglycerin 0.4 MG/HR",
          "type": "DRUG"
        },
        {
          "name": "Nitroglycerin 0.6 MG/HR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 13,
      "start_date": "2011-01",
      "completion_date": "2016-10",
      "has_results": true,
      "last_update_posted_date": "2021-01-14",
      "last_synced_at": "2026-09-09T23:11:35.311Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01407107"
    },
    {
      "nct_id": "NCT03784326",
      "title": "Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clinical Stage II Esophageal Adenocarcinoma AJCC v8",
        "Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8",
        "Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8",
        "Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Clinical Stage III Esophageal Adenocarcinoma AJCC v8",
        "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Pathologic Stage II Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Pathologic Stage III Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Conventional Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Tiragolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2019-02-19",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-28",
      "last_synced_at": "2026-09-09T23:11:35.311Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03784326"
    },
    {
      "nct_id": "NCT00277017",
      "title": "Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, & Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Kidney",
        "Cancer"
      ],
      "interventions": [
        {
          "name": "5-Flourouracil, Interferon-a, IL-2 and Thalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New Mexico Cancer Research Alliance",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 15,
      "start_date": "2000-09",
      "completion_date": "2005-08",
      "has_results": false,
      "last_update_posted_date": "2011-09-27",
      "last_synced_at": "2026-09-09T23:11:35.311Z",
      "location_count": 3,
      "location_summary": "Albuquerque, New Mexico • Santa Fe, New Mexico",
      "locations": [
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Santa Fe",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00277017"
    },
    {
      "nct_id": "NCT03279328",
      "title": "Evaluating Skin Appearance Following 5-Flourouracil Cream for Treatment of Actinic Keratosis and the Effects of Topical Agents",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Actinic Keratoses"
      ],
      "interventions": [
        {
          "name": "Topical Steroid Ointment",
          "type": "DRUG"
        },
        {
          "name": "Vaseline",
          "type": "OTHER"
        },
        {
          "name": "Skin Barrier Moisturier",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Arizona",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2017-10-10",
      "completion_date": "2018-07-31",
      "has_results": false,
      "last_update_posted_date": "2019-06-25",
      "last_synced_at": "2026-09-09T23:11:35.311Z",
      "location_count": 1,
      "location_summary": "Tucson, Arizona",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03279328"
    },
    {
      "nct_id": "NCT00024141",
      "title": "Irinotecan Followed by Fluorouracil in Treating Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "irinotecan hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2001-05",
      "completion_date": "2003-01",
      "has_results": false,
      "last_update_posted_date": "2011-03-07",
      "last_synced_at": "2026-09-09T23:11:35.311Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00024141"
    },
    {
      "nct_id": "NCT00023959",
      "title": "Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma",
        "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity",
        "Recurrent Basal Cell Carcinoma of the Lip",
        "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Lymphoepithelioma of the Nasopharynx",
        "Recurrent Lymphoepithelioma of the Oropharynx",
        "Recurrent Metastatic Squamous Neck Cancer With Occult Primary",
        "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity",
        "Recurrent Salivary Gland Cancer",
        "Recurrent Squamous Cell Carcinoma of the Hypopharynx",
        "Recurrent Squamous Cell Carcinoma of the Larynx",
        "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Recurrent Squamous Cell Carcinoma of the Nasopharynx",
        "Recurrent Squamous Cell Carcinoma of the Oropharynx",
        "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Verrucous Carcinoma of the Larynx",
        "Recurrent Verrucous Carcinoma of the Oral Cavity",
        "Stage III Adenoid Cystic Carcinoma of the Oral Cavity",
        "Stage III Basal Cell Carcinoma of the Lip",
        "Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity",
        "Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity",
        "Stage III Lymphoepithelioma of the Nasopharynx",
        "Stage III Lymphoepithelioma of the Oropharynx",
        "Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity",
        "Stage III Mucoepidermoid Carcinoma of the Oral Cavity",
        "Stage III Salivary Gland Cancer",
        "Stage III Squamous Cell Carcinoma of the Hypopharynx",
        "Stage III Squamous Cell Carcinoma of the Larynx",
        "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage III Squamous Cell Carcinoma of the Nasopharynx",
        "Stage III Squamous Cell Carcinoma of the Oropharynx",
        "Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Stage III Verrucous Carcinoma of the Larynx",
        "Stage III Verrucous Carcinoma of the Oral Cavity",
        "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity",
        "Stage IV Basal Cell Carcinoma of the Lip",
        "Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity",
        "Stage IV Lymphoepithelioma of the Nasopharynx",
        "Stage IV Lymphoepithelioma of the Oropharynx",
        "Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity",
        "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity",
        "Stage IV Salivary Gland Cancer",
        "Stage IV Squamous Cell Carcinoma of the Hypopharynx",
        "Stage IV Squamous Cell Carcinoma of the Larynx",
        "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IV Squamous Cell Carcinoma of the Nasopharynx",
        "Stage IV Squamous Cell Carcinoma of the Oropharynx",
        "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IV Verrucous Carcinoma of the Larynx",
        "Stage IV Verrucous Carcinoma of the Oral Cavity",
        "Untreated Metastatic Squamous Neck Cancer With Occult Primary"
      ],
      "interventions": [
        {
          "name": "hydroxyurea",
          "type": "DRUG"
        },
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2001-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-07",
      "last_synced_at": "2026-09-09T23:11:35.311Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00023959"
    },
    {
      "nct_id": "NCT03421353",
      "title": "AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumours"
      ],
      "interventions": [
        {
          "name": "AZD9150",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "5-Flourouracil",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 76,
      "start_date": "2018-02-07",
      "completion_date": "2024-03-28",
      "has_results": false,
      "last_update_posted_date": "2024-08-21",
      "last_synced_at": "2026-09-09T23:11:35.311Z",
      "location_count": 6,
      "location_summary": "Lafayette, Indiana • Oklahoma City, Oklahoma • Nashville, Tennessee + 3 more",
      "locations": [
        {
          "city": "Lafayette",
          "state": "Indiana"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03421353"
    }
  ]
}